Company profile
Ticker
KNSA
Exchange
Website
CEO
Mr. Sanj K. Patel
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Kiniksa Pharmaceuticals, Ltd.
SEC CIK
Corporate docs
Subsidiaries
Kiniksa Pharmaceuticals Corp. • Kiniksa Pharmaceuticals (France) SARL • Kiniksa Pharmaceuticals (Germany) GmbH • Kiniksa Pharmaceuticals GmbH • Kiniksa Pharmaceuticals (UK), Ltd. • Primatope Therapeutics, Inc. ...
KNSA stock data
Latest filings (excl ownership)
8-K
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
13 Jan 25
10-Q
2024 Q3
Quarterly report
29 Oct 24
8-K
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
29 Oct 24
8-K
Departure of Directors or Certain Officers
7 Oct 24
10-Q
2024 Q2
Quarterly report
25 Jul 24
8-K
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
23 Jul 24
EFFECT
Notice of effectiveness
5 Jul 24
EFFECT
Notice of effectiveness
5 Jul 24
EFFECT
Notice of effectiveness
1 Jul 24
15-15D
Suspension of duty to report
28 Jun 24
Transcripts
KNSA
Earnings call transcript
2024 Q3
29 Oct 24
KNSA
Earnings call transcript
2024 Q2
23 Jul 24
KNSA
Earnings call transcript
2024 Q1
23 Apr 24
KNSA
Earnings call transcript
2023 Q4
28 Feb 24
KNSA
Earnings call transcript
2023 Q3
31 Oct 23
KNSA
Earnings call transcript
2023 Q2
25 Jul 23
KNSA
Earnings call transcript
2023 Q2
25 Jul 23
KNSA
Earnings call transcript
2023 Q1
2 May 23
KNSA
Earnings call transcript
2023 Q1
2 May 23
KNSA
Earnings call transcript
2022 Q4
28 Feb 23
Latest ownership filings
SC 13G/A
Fairmount Funds Management LLC
14 Feb 25
4
Eben Tessari
12 Feb 25
144
Notice of proposed sale of securities
10 Feb 25
4
Eben Tessari
15 Jan 25
144
Notice of proposed sale of securities
13 Jan 25
4
Eben Tessari
18 Dec 24
144
Notice of proposed sale of securities
16 Dec 24
4
Mark Ragosa
10 Dec 24
4
Mark Ragosa
5 Dec 24
144
Notice of proposed sale of securities
3 Dec 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 97.38 mm | 97.38 mm | 97.38 mm | 97.38 mm | 97.38 mm | 97.38 mm |
Cash burn (monthly) | 631.67 k | 1.70 mm | 3.22 mm | 1.79 mm | 745.33 k | (no burn) |
Cash used (since last report) | 2.96 mm | 7.98 mm | 15.08 mm | 8.37 mm | 3.49 mm | n/a |
Cash remaining | 94.42 mm | 89.39 mm | 82.30 mm | 89.01 mm | 93.89 mm | n/a |
Runway (months of cash) | 149.5 | 52.5 | 25.6 | 49.8 | 126.0 | n/a |
Institutional ownership, Q3 2024
54.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 172 |
Opened positions | 172 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 974.15 bn |
Total shares | 39.39 mm |
Total puts | 101.40 k |
Total calls | 123.50 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 3.82 mm | $95.39 bn |
Vanguard | 3.30 mm | $82.42 bn |
Fairmount Funds Management | 3.20 mm | $80.09 bn |
Braidwell | 2.89 mm | $72.33 bn |
Baker Bros. Advisors | 2.82 mm | $70.43 bn |
Rubric Capital Management | 2.42 mm | $60.45 bn |
Hillhouse Capital Advisors | 1.58 mm | $39.55 bn |
Pictet Asset Management Holding | 1.21 mm | $30.18 bn |
MS Morgan Stanley | 1.03 mm | $25.63 bn |
Parkman Healthcare Partners | 755.24 k | $18.87 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Feb 25 | Eben Tessari | Class A Ordinary Share | Sell | Dispose S | No | Yes | 19.57 | 14,000 | 273.98 k | 81,975 |
10 Feb 25 | Eben Tessari | Class A Ordinary Share | Option exercise | Acquire M | No | Yes | 3.8 | 7,000 | 26.60 k | 95,975 |
10 Feb 25 | Eben Tessari | Share Option Class A Ordinary Share | Option exercise | Dispose M | No | Yes | 3.8 | 7,000 | 26.60 k | 21,049 |
13 Jan 25 | Eben Tessari | Class A Ordinary Share | Sell | Dispose S | No | Yes | 19.08 | 1,677 | 32.00 k | 88,975 |
13 Jan 25 | Eben Tessari | Class A Ordinary Share | Sell | Dispose S | No | Yes | 18.13 | 12,323 | 223.42 k | 90,652 |
13 Jan 25 | Eben Tessari | Class A Ordinary Share | Option exercise | Acquire M | No | Yes | 3.8 | 7,000 | 26.60 k | 102,975 |
13 Jan 25 | Eben Tessari | Share Option Class A Ordinary Share | Option exercise | Dispose M | No | Yes | 3.8 | 7,000 | 26.60 k | 28,049 |
16 Dec 24 | Eben Tessari | Class A Ordinary Share | Sell | Dispose S | No | Yes | 20.44 | 23,017 | 470.47 k | 95,975 |
16 Dec 24 | Eben Tessari | Class A Ordinary Share | Option exercise | Acquire M | No | Yes | 1.59 | 16,017 | 25.47 k | 118,992 |
16 Dec 24 | Eben Tessari | Share Option Class A Ordinary Share | Option exercise | Dispose M | No | Yes | 1.59 | 16,017 | 25.47 k | 0 |
Press releases
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
1mo ago
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
1mo ago
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
2mo ago